Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis

Authors: Pei-Yun Zhou, Zheng Tang, Wei-Ren Liu, Meng-Xin Tian, Lei Jin, Xi-Fei Jiang, Han Wang, Chen-Yang Tao, Zhen-Bin Ding, Yuan-Fei Peng, Shuang-Jian Qiu, Zhi Dai, Jian Zhou, Jia Fan, Ying-Hong Shi

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Whether perioperative blood transfusions (PBTs) adversely influence oncological outcomes for intrahepatic cholangiocarcinoma (ICC) patients after curative resection remains undetermined.

Methods

Of the 605 patients who underwent curative liver resection for ICC between 2000 and 2012, 93 received PBT. We conducted Cox regression and variable selection logistic regression analyses to identify confounding factors of PBT. Propensity score matching (PSM) and Cox regression analyses were used to compare the overall survival (OS) and disease-free survival (DFS) between the patients with or without PBT.

Results

After exclusion, 93 eligible patients (15.4%) received PBT, compared with 512 (84.6%) who did not receive PBT; the groups were highly biased in terms of the propensity score (PS) analysis (0.096 ± 0.104 vs. 0.479 ± 0.372, p < 0.001). PBT was associated with an increased risk of OS (HR: 1.889, 95% CI: 1.446–2.468, p < 0.001) and DFS (HR: 1.589, 95% CI: 1.221–2.067, p < 0.001) in the entire cohort. After propensity score matching (PSM), no bias was observed between the groups (PS,0.136 ± 0.117 VS. 0.193 ± 0.167, p = 0.785). In the multivariate Cox analysis, PBT was not associated with increased risks of OS (HR: 1.172, 95% CI: 0.756–1.816, p = 0.479) and DFS (HR: 0.944, 95% CI: 0.608–1.466, p = 0.799). After propensity score adjustment, PBT was still not associated with OS or DFS after ICC curative resection.

Conclusions

The present study found that PBT did not affect DFS and OS after curative resection of ICC.
Literature
1.
go back to reference Torre LA, Sauer AMG, Chen MS, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, native Hawaiians, and Pacific islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66(3):182–202.CrossRefPubMedPubMedCentral Torre LA, Sauer AMG, Chen MS, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, native Hawaiians, and Pacific islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66(3):182–202.CrossRefPubMedPubMedCentral
2.
go back to reference Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surgeons. 2013;217(4):736–50.CrossRef Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al. Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surgeons. 2013;217(4):736–50.CrossRef
3.
go back to reference Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
4.
5.
go back to reference Chen W, Zheng R, Zhang S. Liver cancer incidence and mortality in China, 2009. Chinese J Cancer. 2013;32(4):162–9.CrossRef Chen W, Zheng R, Zhang S. Liver cancer incidence and mortality in China, 2009. Chinese J Cancer. 2013;32(4):162–9.CrossRef
6.
go back to reference Xue L, Chen X, Wei-Han Z, Yang K, Chen X, Zhang B, et al. Impact of perioperative blood transfusion on postoperative complications and prognosis of gastric adenocarcinoma patients with different preoperative hemoglobin value. Gastroent Res Pract. 2016;(1):1–10. Xue L, Chen X, Wei-Han Z, Yang K, Chen X, Zhang B, et al. Impact of perioperative blood transfusion on postoperative complications and prognosis of gastric adenocarcinoma patients with different preoperative hemoglobin value. Gastroent Res Pract. 2016;(1):1–10.
7.
go back to reference Mavros MN, Xu L, Maqsood H, Gani F, Ejaz A, Spolverato G, et al. Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(13):4382–91.CrossRefPubMed Mavros MN, Xu L, Maqsood H, Gani F, Ejaz A, Spolverato G, et al. Perioperative blood transfusion and the prognosis of pancreatic cancer surgery: systematic review and meta-analysis. Ann Surg Oncol. 2015;22(13):4382–91.CrossRefPubMed
8.
go back to reference Kimura N, Toyoki Y, Ishido K, Kudo D, Yakoshi Y, Tsutsumi S, et al. Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma. J Gastrointest Surg. 2015;19(5):866–79.CrossRefPubMedPubMedCentral Kimura N, Toyoki Y, Ishido K, Kudo D, Yakoshi Y, Tsutsumi S, et al. Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma. J Gastrointest Surg. 2015;19(5):866–79.CrossRefPubMedPubMedCentral
9.
go back to reference Müller SA, Mehrabi A, Rahbari NN, Warschkow R, Elbers H, Leowardi C, et al. Allogeneic blood transfusion does not affect outcome after curative resection for advanced cholangiocarcinoma. Ann Surg Oncol. 2014;21(1):155–64.CrossRefPubMed Müller SA, Mehrabi A, Rahbari NN, Warschkow R, Elbers H, Leowardi C, et al. Allogeneic blood transfusion does not affect outcome after curative resection for advanced cholangiocarcinoma. Ann Surg Oncol. 2014;21(1):155–64.CrossRefPubMed
10.
go back to reference De Boer MT, Molenaar IQ, Porte RJ: Impact of blood loss on outcome after liver resection. Digest Surg 2007, 24(4):259–264. De Boer MT, Molenaar IQ, Porte RJ: Impact of blood loss on outcome after liver resection. Digest Surg 2007, 24(4):259–264.
11.
go back to reference Warschkow R, Güller U, Köberle D, Müller SA, Steffen T, Thurnheer M, et al. Perioperative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. Ann Surg. 2014;259(1):131–8.CrossRefPubMed Warschkow R, Güller U, Köberle D, Müller SA, Steffen T, Thurnheer M, et al. Perioperative blood transfusions do not impact overall and disease-free survival after curative rectal cancer resection. Ann Surg. 2014;259(1):131–8.CrossRefPubMed
12.
go back to reference Yang T, Lu J, Lau WY, Zhang T, Zhang H, Shen Y, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma a propensity score matching analysis. J Hepatol. 2016;64:583–93.CrossRefPubMed Yang T, Lu J, Lau WY, Zhang T, Zhang H, Shen Y, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma a propensity score matching analysis. J Hepatol. 2016;64:583–93.CrossRefPubMed
13.
go back to reference Rizvi S, Gores GJ. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma 2013 Gastroenterology. Gastroenterol. 2013(145):1215–29. Rizvi S, Gores GJ. Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma 2013 Gastroenterology. Gastroenterol. 2013(145):1215–29.
14.
go back to reference Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med. 2014;127(2):124–31.CrossRefPubMed Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical outcomes: a meta-analysis and systematic review. Am J Med. 2014;127(2):124–31.CrossRefPubMed
15.
go back to reference Abadie A, Angrist J, Guido I. Instrumental variable estimates of the effect of subsidized training on the quantile of trainee earnings. Econometrica. 2002;70(1):91–117.CrossRef Abadie A, Angrist J, Guido I. Instrumental variable estimates of the effect of subsidized training on the quantile of trainee earnings. Econometrica. 2002;70(1):91–117.CrossRef
16.
go back to reference Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010;59(3):387–96.CrossRefPubMed Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010;59(3):387–96.CrossRefPubMed
17.
go back to reference Abadie A, Imbens GW. Bias-corrected matching estimators for average treatment effects. J Bus Econ Stat. 2011;29(1):1–11.CrossRef Abadie A, Imbens GW. Bias-corrected matching estimators for average treatment effects. J Bus Econ Stat. 2011;29(1):1–11.CrossRef
18.
19.
go back to reference Kim DH, Pieper CF, Ahmed A, Colón-Emeric CS. Use and interpretation of propensity scores in aging research: a guide for clinical researchers. J Am Geriatr Soc. 2016;64(10):2065–73.CrossRefPubMedPubMedCentral Kim DH, Pieper CF, Ahmed A, Colón-Emeric CS. Use and interpretation of propensity scores in aging research: a guide for clinical researchers. J Am Geriatr Soc. 2016;64(10):2065–73.CrossRefPubMedPubMedCentral
21.
go back to reference Dupont WD, Plummer WD. Power and sample size calculations. Control Clin Trials. 1990;11(2):116–28.CrossRefPubMed Dupont WD, Plummer WD. Power and sample size calculations. Control Clin Trials. 1990;11(2):116–28.CrossRefPubMed
22.
go back to reference Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;19(6):589–601.CrossRefPubMed Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials. 1998;19(6):589–601.CrossRefPubMed
24.
go back to reference Han S, Kim G, Ko JS, Sinn DH, Yang JD, Joh J, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. Ann Surg. 2016;264(2):339–43.CrossRefPubMed Han S, Kim G, Ko JS, Sinn DH, Yang JD, Joh J, et al. Safety of the use of blood salvage and autotransfusion during liver transplantation for hepatocellular carcinoma. Ann Surg. 2016;264(2):339–43.CrossRefPubMed
25.
go back to reference Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012;256(2):235–44.CrossRefPubMed Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis. Ann Surg. 2012;256(2):235–44.CrossRefPubMed
26.
go back to reference Wada H, Eguchi H, Nagano H, Kubo S, Nakai T, Kaibori M, et al. Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular surgery: a multi-center analysis. Surg Today. 2017; Wada H, Eguchi H, Nagano H, Kubo S, Nakai T, Kaibori M, et al. Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular surgery: a multi-center analysis. Surg Today. 2017;
27.
go back to reference Baek S. Propensity score matching: a conceptual review for radiology researchers. Korean Soc Radiol. 2015;16(2):286–96.CrossRef Baek S. Propensity score matching: a conceptual review for radiology researchers. Korean Soc Radiol. 2015;16(2):286–96.CrossRef
Metadata
Title
Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis
Authors
Pei-Yun Zhou
Zheng Tang
Wei-Ren Liu
Meng-Xin Tian
Lei Jin
Xi-Fei Jiang
Han Wang
Chen-Yang Tao
Zhen-Bin Ding
Yuan-Fei Peng
Shuang-Jian Qiu
Zhi Dai
Jian Zhou
Jia Fan
Ying-Hong Shi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3745-z

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine